Rechallenge With Immunotherapy for ES‐SCLC: Efficacy and Safety From a Retrospective Propensity Score‐Matched Study Authors: Yuxia Wang, Yunfeng Tong, Yang Pan, Xinyue Li, Hui Li Published: 2026 ABSTRACT ABSTRACTBackgroundAlthough immunotherapy combined with platinum‐based chemotherapy is now the standard first‐line treatment for extensive‐stage small cell lung cancer (ES‐SCLC), the benefit of continuing immune checkpoint inhibitors (ICIs) after disease progression (PD) remains uncertain. This real‐world study assessed the efficacy and safety of second‐line immunotherapy in ES‐SCLC patients using propensity score matching (PSM).MethodsES‐SCLC patients who received second‐line treatments following first‐line chemoimmunotherapy at Zhejiang Cancer Hospital from January 2019 to December 2023 were included. Clinical baseline characteristics were collected and balanced. The efficacy and safety of patients who continued to receive second‐line immunotherapy were compared with those who did not.ResultsA total of 187 patients were analyzed. The median overall survival (OS) and progression‐free survival (PFS) for the entire cohort were 8.5 months (95% CI: 7.1–9.9) and 3.3 months (95% CI: 2.5–4.1), respectively. After PSM, each group included 76 patients. No significant differences in OS (median OS: 8.3 vs. 7.8 months; HR, 0.97; 95% CI: 0.68–1.39; p = 0.87) or PFS (median PFS: 3.45 vs. 3.1 months; HR, 1.07; 95% CI: 0.77–1.49; p = 0.69) were observed between the rechallenge and non‐rechallenge groups. Subgroup analysis suggested in an exploratory manner that immunotherapy rechallenge was associated with poorer outcomes in non‐smokers (mOS: 8 vs. 16.6 months; HR, 2.9; 95% CI: 1.1–7.9; p = 0.004). The rate of all‐grade immune‐related adverse events (irAEs) was higher in the rechallenge group (36.8% vs. 17.1%).ConclusionRechallenge with immunotherapy after first‐line chemoimmunotherapy may not demonstrate a significant survival benefit in ES‐SCLC patients, particularly among never smokers, and may lead to more frequent irAEs.Keywords: efficacy, immunotherapy rechallenge, safety, small cell lung cancer Abbreviations adverse events confidence intervals complete response Common Terminology Criteria for Adverse Events disease control rate duration of response Eastern Cooperative Oncology Group extensive‐stage small cell lung cancer hazard ratios immune checkpoint inhibitors immune‐related adverse events neuroendocrine objective response rate overall survival progressive disease programmed cell death protein 1 programmed cell death ligand 1 progression‐free survival partial response propensity score matching response evaluation criteria in solid tumors stable disease standardized mean differences tumor‐associated macrophage tumor mutational burden tumor microenvironment Introduction Small‐cell lung cancer (SCLC), a highly aggressive neuroendocrine malignancy, represents approximately 15% of all lung cancers and is characterized by rapid growth, early dissemination, and poor prognosis [1, 2]. For extensive‐stage SCLC (ES‐SCLC), platinum‐etoposide chemotherapy had long been the mainstay of treatment, typically resulting in a median overall survival (OS) of under 10 months [3]. The introduction of immune checkpoint inhibitors (ICIs), specifically PD‐1/PD‐L1 inhibitors, into first‐line therapy has reshaped the treatment approach [4, 5, 6]. Key trials such as IMpower133 and CASPIAN showed that combining atezolizumab or durvalumab with chemotherapy increased median OS to 12.3–13.0 months, thereby establishing chemoimmunotherapy as the standard first‐line protocol [7, 8]. More recently, Phase III studies ASTRUM‐005 and CAPSTONE‐1 have further advanced the field, with cohorts treated with serplulimab and adebrelimab achieving median OS of 15.4 and 15.3 months, respectively, confirming the broader relevance of PD‐1/PD‐L1 blockade [9, 10]. Despite these developments, disease progression remains nearly inevitable, with most patients experiencing relapse or advancement within months, and a 5‐year survival rate below 10%, highlighting the urgent demand for effective second‐line options [11, 12]. Post‐immunotherapy progression presents a distinct therapeutic challenge. Conventional second‐line agents, such as topotecan, provide limited benefit, with objective response rates (ORRs) rarely exceeding 25% and median OS typically falling between 6 and 9 months. The value of continuing ICIs beyond progression remains uncertain [5, 13]. Although recent studies have explored the potential of reintroducing ICIs in subsequent treatment lines [14, 15], evidence supporting this strategy in ES‐SCLC is still limited. A study by Shang et al. offered a new perspective, suggesting that patients with fewer than four metastatic sites might experience prolonged survival with ICI rechallenge [16]. Drawing on data from the IMpower133 trial and a real‐world cohort, the authors reported that retreatment with atezolizumab altered the tumor microenvironment (TME), characterized by lower M2 macrophage infiltration and higher CD4 naïve T cell activity, which aligned with improved OS. However, their findings are tempered by notable limitations: the study lacked thorough adjustment for baseline confounding factors such as smoking history and ECOG performance status, and it did not provide a full assessment of tumor response or safety outcomes across a broader ES‐SCLC population. Although individual case reports, such as Zhang et al., describe clinical benefit from rechallenge with alternative ICIs, these remain anecdotal and do not offer a solid foundation for clinical decision‐making [17]. Taken together, these limitations emphasize the need for well‐designed, systematic studies to better define the role of ICI rechallenge in ES‐SCLC. To address this, we conducted a real‐world retrospective analysis involving a relatively large patient cohort, using propensity score matching (PSM) to rigorously balance baseline clinical characteristics. Our objective was to assess the efficacy and safety of ICI‐based therapy in advanced SCLC patients previously treated with ICIs who had experienced disease progression, and to investigate whether specific subgroups might benefit more clearly from this treatment approach. Methods Study Design and Data Collection This retrospective study was conducted at Zhejiang Cancer Hospital and included patients diagnosed with ES‐SCLC who experienced disease progression after receiving first‐line immunotherapy combined with platinum‐based chemotherapy between January 2019 and December 2023. The study aimed to evaluate the effect of immunotherapy rechallenge on treatment efficacy and safety in this population. A total of 187 patients were initially identified from the hospital's electronic medical records. Inclusion criteria were: (1) histologically or cytologically confirmed ES‐SCLC; (2) first‐line treatment with immunotherapy combined with platinum‐based chemotherapy; (3) progression of disease (PD) following first‐line therapy [18]; (4) administration of at least two cycles of second‐line treatment; and (5) availability of complete medical records. Patients were excluded if they had received fewer than two cycles of either first‐line or second‐line therapy or if their records were incomplete. The study protocol was approved by the ethics committee of Zhejiang Cancer Hospital, in line with the ethical standards for research involving human subjects. Treatment Patients were divided into two groups based on their second‐line treatment approach. The rechallenge group (n = 95) consisted of patients who continued immunotherapy, either the same or a different ICI, in the second‐line setting [19]. Patients receiving second‐line immunotherapy were also treated with chemotherapy or targeted therapy, the distribution of which is detailed in Table 1. The non‐rechallenge group (n = 92) included patients who discontinued immunotherapy and received other forms of second‐line therapy such as chemotherapy or targeted agents. To reduce potential confounding factors, PSM was used to balance baseline characteristics between the two groups, including age, sex, smoking history, Eastern Cooperative Oncology Group (ECOG) performance status, tumor stage, and metastatic sites [20]. After matching, 76 patients remained in each group for comparative analysis. TABLE 1Patient demographics and baseline characteristics.Clinical characteristic, N = 152Non‐rechallenge (n = 76)Rechallenge (n = 76) p Sex, n (%)0.158Female14 (18.4)7 (9.2)Male62 (81.6)69 (90.8)Age, n (%)0.745≤ 6541 (53.9)38 (50.0)> 6535 (46.1)38 (50.0)Smoking history, n (%)0.116Smoker or ex‐smoker55 (72.4)64 (84.2)Never smoker21 (27.6)12 (15.8)ECOG PS, n (%)1.0000–172 (94.7)71 (93.4)≥ 24 (5.3)5 (6.6)Tumor stage, n (%)1.000IIIc3 (3.9)2 (2.6)IV73 (96.1)74 (97.4)Liver metastases, n (%)0.409No42 (55.3)48 (63.2)Yes34 (44.7)28 (36.8)Brain metastases, n (%)1.000No45 (59.2)44 (57.9)Yes31 (40.8)32 (42.1)Bone metastases, n (%)0.742No46 (60.5)43 (56.6)Yes30 (39.5)33 (43.4)PFS of first‐line therapy, n (%)0.330≥ 6 months35 (46.1)42 (55.3)< 6 months41 (53.9)34 (44.7)Best response to first‐line therapy, n (%)0.592CR/PR56 (73.7)52 (68.4)SD/PD20 (26.3)24 (31.6)Type of progression after first‐line therapy, n (%)1.000Oligoprogression39 (51.3)40 (52.6)Systemic progression37 (48.7)36 (47.4)Second‐line therapy regimen, n (%)1.000Chemotherapy67 (88.2)66 (86.8)Nab‐paclitaxel ± platinum drugs28 (36.9)35 (46.0)Irinotecan ± platinum drugs39 (51.3)31 (40.8)Targeted therapy9 (11.8)10 (13.2)PCI, n (%)0.326No69 (90.8)73 (96.1)Yes7 (9.2)3 (3.9)Abbreviations: CR, complete response; ECOG PS, Eastern Cooperative Oncology Group Performance Status; PD, progressive disease; PR, partial response; SD, stable disease. Patient demographics and baseline characteristics. Abbreviations: CR, complete response; ECOG PS, Eastern Cooperative Oncology Group Performance Status; PD, progressive disease; PR, partial response; SD, stable disease. Data collection was conducted by reviewing electronic medical records and included demographic information, clinical features, treatment history, and clinical outcomes. Key variables included age, sex, smoking status, ECOG performance status, tumor stage, presence of liver, brain, or bone metastases, administration of prophylactic cranial irradiation, progression‐free survival (PFS) during first‐line therapy, best response to first‐line treatment, pattern of progression (oligoprogression or systemic), and second‐line regimen. Tumor responses, complete response (CR), partial response (PR), stable disease (SD), and PD were evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [18]. Adverse events (AEs) related to second‐line treatment, including immune‐related adverse events (irAEs), were also collected and graded following the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [21]. Follow‐Up and Endpoints Follow‐up data were collected through hospital records and telephone interviews. The primary endpoint was OS, defined as the interval from the initiation of second‐line therapy to death from any cause or the last follow‐up. Secondary endpoints included PFS, measured from the start of second‐line therapy to the date of disease progression or death, whichever occurred first. ORR was calculated as the combined percentage of CR and PR, while disease control rate (DCR) included CR, PR, and SD. Duration of response (DOR) was defined as the time from the first documented CR or PR to the first recorded progression or death from any cause. Patients lost to follow‐up or still alive at the time of data cutoff were censored in the survival analysis. The final date for follow‐up was November 22, 2024. Statistical Analysis All statistical analyses were performed using SPSS version 27.0 and R version 4.4.2. Baseline characteristics between the rechallenge and non‐rechallenge groups were compared using chi‐square tests or Fisher's exact test, as appropriate. To address potential confounding and ensure comparability, PSM was applied with a 1:1 nearest‐neighbor algorithm and a caliper of 0.05. Propensity scores were generated based on variables including ECOG performance status and liver metastases in baseline, best response and PFS of first‐line therapy, and different treatment regimens in second line. After PSM, the standardized mean differences (SMD) values of each covariate were less than 0.1 (Table S1). Survival outcomes (OS and PFS) were estimated using the Kaplan–Meier method and compared between groups with the log‐rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using the Cox proportional hazards model. Subgroup analyses were conducted to explore differences in survival outcomes based on clinical factors such as age, sex, smoking status, ECOG score, tumor stage, and metastatic site. The subgroup analyses were exploratory in nature and were not adjusted for multiple testing. Forest plots were used to display the results of these subgroup analyses. AEs were summarized descriptively. irAEs were analyzed separately, and their incidence and severity were compared between the two groups. p < 0.05 were considered statistically significant. Results Patient Characteristics Between January 2019 and December 2023, a retrospective review identified 1017 patients with ES‐SCLC who received first‐line treatment at our center. After excluding 642 patients who did not meet the eligibility criteria, 375 patients proceeded to second‐line therapy. Of these, 188 were excluded due to incomplete medical records or receipt of fewer than two cycles of second‐line therapy. Ultimately, 187 patients met the inclusion criteria, with 95 assigned to the immunotherapy rechallenge group and 92 to the non‐rechallenge group. Following 1:1 PSM, 76 patients were included in each group for further analysis. The process of patient enrollment and exclusion is outlined in Figure 1. After PSM, demographic and baseline clinical characteristics were well balanced between the two groups (Table 1). The process of patient enrollment and exclusion. Survival Outcomes In the entire cohort, the median OS was 8.5 months (95% CI: 7.1–9.9), and the median PFS was 3.3 months (95% CI: 2.5–4.1) (Figure 2A,B). Post‐PSM analysis showed no significant difference in OS between the rechallenge and non‐rechallenge groups (median OS: 8.3 vs. 7.8 months; HR = 0.97, 95% CI: 0.68–1.39; p = 0.87). Similarly, median PFS was comparable between groups (3.45 vs. 3.10 months; HR = 1.07, 95% CI: 0.77–1.49; p = 0.69) (Figure 3A,B). (A) The median OS was 8.5 months (95% CI: 7.1–9.9) in the entire cohort. (B) The median PFS was 3.3 months (95% CI: 2.5–4.1) in the entire cohort. (A) The OS between the rechallenge and non‐rechallenge groups (median OS: 8.3 vs. 7.8 months; HR = 0.97, 95% CI: 0.68–1.39; p = 0.87). (B) The PFS between the rechallenge and non‐rechallenge groups (3.45 vs. 3.10 months; HR = 1.07, 95% CI: 0.77–1.49; p = 0.69). Subgroup analysis indicated that never‐smokers in the rechallenge group had significantly worse OS compared to those in the non‐rechallenge group (mOS: 8.0 vs. 16.6 months; HR, 2.9; 95% CI: 1.1–7.9; p = 0.004) (Figure 4A). However, this analysis is limited by the very small sample size (n = 12 never‐smokers in the rechallenge group) and should be interpreted as hypothesis‐generating. In contrast, no significant OS difference was observed among current or former smokers (mOS: 8.4 vs. 6.9 months; HR = 0.7, 95% CI: 0.5–1.1; p = 0.106) (Figure 4B). Other subgroups, including age, ECOG performance status, tumor stage, and metastatic sites, did not show significant differences in OS between the two treatment groups (Figure 5). Furthermore, we explored whether the type of ICI agent (same vs. different) influenced outcomes within the rechallenge group. In our study, the majority of patients in the rechallenge group (84.2%, n = 64) continued the same ICI agent used in the first‐line setting, while a smaller subset (15.8%, n = 12) was switched to a different ICI. Further analysis revealed that there was no statistically significant difference in OS between these two subgroups (p = 0.13, Figure S1). (A) The OS between the rechallenge and non‐rechallenge groups in non‐smoker population (mOS: 8.0 vs. 16.6 months; HR, 2.9; 95% CI: 1.1–7.9; p = 0.004). (B) The OS between the rechallenge and non‐rechallenge groups in smoker or ex‐smoker populations (mOS: 8.4 vs. 6.9 months; HR = 0.7, 95% CI: 0.5–1.1; p = 0.106). Forest plot of subgroup analysis of survival according to clinical variables in ES‐SCLC patients between the rechallenge and non‐rechallenge groups. Clinical variables include age, sex, ECOG performance status, tumor stage, and metastatic sites. Tumor Response In the comparison of therapeutic outcomes, the rechallenge group showed a numerically higher ORR than the non‐rechallenge group (22.3% vs. 15.8%; p = 0.23). For disease control, the rechallenge group also demonstrated a higher DCR of 61.8% compared to 50.0% in the non‐rechallenge group (p = 0.67). As for response durability, the median DOR was similar between groups, measuring 3.3 months (95% CI: 2.6–4.0) in the rechallenge group and 2.9 months (95% CI: 2.7–8.1) in the non‐rechallenge group (p = 0.49) (Table 2). TABLE 2Summary of tumor response.Non‐rechallenge (n = 76)Rechallenge (n = 76) p Best overall response, n (%)Complete response0 (0)0 (0)Partial response12 (15.8)17 (22.3)Stable disease26 (34.2)30 (39.5)Progressive disease38 (50.0)29 (38.2)Objective response, n (%)12 (15.8)17 (22.3)0.23Disease control, n (%)38 (50.0)47 (61.8)0.67Duration of objective response (months)Median (95% CI)2.9 (2.7–8.1)3.3 (2.6–4.0)0.49 Summary of tumor response. AEs The overall incidence of any‐grade AEs was comparable between the rechallenge group (89.5%) and the non‐rechallenge group (88.2%). However, grade ≥ 3 AEs occurred more frequently in the non‐rechallenge group (19.7% vs. 14.5%). In the non‐rechallenge group, common AEs included anemia (35.5%), leukopenia (30.3%), and fatigue (22.4%). The incidence of any‐grade irAEs was higher in the rechallenge group (36.8% vs. 17.1%), with hypothyroidism being the most frequent (11.8% in the rechallenge group vs. 7.9% in the non‐rechallenge group). Grade ≥ 3 irAEs were more frequent in the rechallenge group (3.9% vs. 0%). Other irAEs, including hyperthyroidism, skin toxicity, adrenal insufficiency, pneumonitis, hepatic toxicity, and so forth, were also more commonly reported in the rechallenge group (Table 3). TABLE 3Drug‐related AEs reported in > 10% of patients.Clinical characteristicsImmunotherapy plus chemotherapy N = 76Chemotherapy, N = 76Any grade, n (%)Grade ≥ 3, n (%)Any grade, n (%)Grade ≥ 3, n (%)Patients with any drug‐related AE68 (89.5)11 (14.5)67 (88.2)15 (19.7)Anemia33 (43.4)2 (2.6)27 (35.5)4 (5.3)Leukopenia19 (25.0)4 (5.3)23 (30.3)7 (9.2)Asthenia19 (25.0)019 (25.0)3 (3.9)Fatigue19 (25.0)017 (22.4)0Platelet count decreased17 (22.4)3 (3.9)11 (14.5)5 (6.6)Neutrophil count decreased14 (18.4)3 (3.9)14 (18.4)4 (5.3)Numbness in the limbs13 (17.1)06 (7.9)0Nausea11 (14.5)09 (11.8)0Decreased appetite8 (10.5)012 (15.8)0Dizzy8 (10.5)05 (6.6)0Pruritus6 (7.9)3 (3.9)2 (2.6)0Rash5 (6.6)1 (1.3)00Constipation5 (6.6)04 (5.3)0Vomiting4 (5.3)02 (2.6)0Muscle pain2 (2.6)05 (6.6)0irAEAll in irAEs28 (36.8)3 (3.9)13 (17.1)0Hypothyroidism9 (11.8)1 (1.3)6 (7.9)0Hyperthyroidism6 (7.9)03 (3.9)0Skin toxicity5 (6.6)1 (1.3)2 (2.6)0Adrenal insufficiency5 (6.6)02 (2.6)0Pneumonitis4 (5.3)1 (1.3)1 (1.3)0Hepatic toxicity2 (2.6)01 (1.3)0Cardiac toxicity2 (2.6)000Gastrointestinal toxicity1 (1.3)000Abbreviation: irAE, immune‐related adverse event. Drug‐related AEs reported in > 10% of patients. Abbreviation: irAE, immune‐related adverse event. Discussion The clinical utility of immunotherapy rechallenge in ES‐SCLC remains unclear, particularly given the limited feasibility of conducting prospective crossover trials in this setting. Within this context, we investigated the question using real‐world data. By applying PSM to adjust for baseline differences, our analysis found no significant improvement in OS or PFS with second‐line immunotherapy rechallenge. Importantly, the rechallenge group experienced a significantly higher rate of irAEs. From a clinical standpoint, these findings offer real‐world, quality‐controlled evidence regarding second‐line treatment strategies for ES‐SCLC. Based on our results, we may not be able to draw conclusions about cross‐line immunotherapy for the general ES‐SCLC population, particularly in unselected patients, as it may not improve survival outcomes and may increase treatment‐related toxicity. As such, the routine use of this approach should be reconsidered with caution. Prior studies have attempted to stratify patients in order to identify those who might benefit from immunotherapy rechallenge. Shang et al. from Shandong Cancer Hospital proposed that certain ES‐SCLC subgroups, such as those with fewer than four metastatic sites, might respond favorably to ICI rechallenge, potentially due to remodeling of the TME [16]. However, their conclusions were based on a combined dataset from the IMpower133 trial and a single‐center real‐world cohort, without proper adjustment for key baseline variables such as smoking history and ECOG performance status. This lack of control for confounding factors raises concerns about selection bias and the potential overestimation of survival benefits. Furthermore, subgroup outcomes were not the primary endpoint of their study, and critical clinical factors such as safety and tumor response were not addressed. Individual case reports [17] have described restored efficacy using alternative ICIs in select patients, but such observations remain anecdotal and lack broader clinical applicability [17]. In contrast, our study used a real‐world cohort with PSM to directly examine the limitations of ICI rechallenge in unselected populations. But prospective clinical trials are warranted and are underway to further define the role and optimal patient selection for immunotherapy rechallenge in ES‐SCLC. In addition, our analysis showed numerically higher ORR (22.3% vs. 15.8%) and DCR (61.8% vs. 50.0%) in the rechallenge group compared to the non‐rechallenge group. However, these differences were not statistically significant (ORR: p = 0.23; DCR: p = 0.67), and the median DOR was nearly identical between groups (3.3 vs. 2.9 months). The observed numerical trend may be associated with the limited sample size and the retrospective design, so we should treat these as a hypothesis‐generating signal. These results suggest that while immunotherapy rechallenge may lead to short‐term disease control in some patients, the clinical gain is limited and may not support its widespread use in unselected ES‐SCLC populations. This conclusion that clinical benefits are limited may be related to the intrinsic immune heterogeneity of SCLC. As highlighted by Nabet et al., SCLC comprises distinct subtypes with divergent immunotherapy responses: T cell‐inflamed, neuroendocrine tumors (SCLC‐I‐NE) exhibit sensitivity to PD‐L1 blockade, while non‐neuroendocrine, TAM‐rich subtypes (SCLC‐I‐nonNE) derive limited benefit [22]. Existing studies have demonstrated that following platinum‐based chemotherapy resistance, SCLC may transition from neuroendocrine subtypes to non‐neuroendocrine subtypes through Notch signaling activation and epigenetic reprogramming. This phenotypic shift might critically explain the lack of benefit observed in this study regarding second‐line continuation of immunotherapy [23, 24, 25]. We further found that most subgroups derived no survival benefit from immunotherapy rechallenge. Neither the depth of response (CR/PR vs. SD/PD) nor a longer duration of benefit from first‐line treatment (PFS ≥ 6 months) was associated with a statistically significant survival advantage from immunotherapy rechallenge in the second‐line setting. This suggests that most clinical classifications may not be able to provide definitive therapeutic guidance for the complex changes in SCLC, and in the future, it should be explored from the level of molecular subtyping. Moreover, we did not find a survival difference between continuing the same drug and switching to a different drug in the rechallenge group. The interpretation of this finding is constrained by the imbalance in subgroup sizes (84.2% same ICI vs. 15.8% different ICI) and the limited statistical power to detect a difference in the smaller cohort. However, our exploratory analysis generated a hypothesis that never‐smokers may derive less benefit from continued immunotherapy. This finding, while based on a small sample size and requiring validation, is biologically plausible. This likely reflects differences in tumor immunogenicity. Tumors in smokers, often associated with higher tumor mutational burden (TMB) and elevated PD‐L1 expression, may respond more readily to ICIs [26, 27, 28]. By contrast, tumors in never‐smokers, frequently marked by low TMB and immune‐cold microenvironments, may evade immune detection more easily [29]. This observation underscores the importance of future research integrating molecular biomarkers to better select patients for treatment beyond progression, rather than supporting a change in clinical practice based on smoking status alone. In addition to limited efficacy, our study placed strong emphasis on safety outcomes. Rechallenge was linked to a significantly higher rate of irAEs (36.8% vs. 17.1%), including severe events of grade ≥ 3 (3.9% vs. 0%), raising concerns about the impact of prolonged ICI exposure on quality of life. While previous trials such as IMpower133 and CASPIAN largely focused on first‐line safety profiles, our findings draw attention to the cumulative toxicity that can emerge with continued immunotherapy, an aspect that has received little attention in rechallenge contexts [7, 8]. Notably, immune‐related thyroid dysfunction was more frequently observed in the rechallenge group, consistent with emerging reports of increased irAEs under extended ICI use [21]. These safety signals, coupled with the marginal clinical benefit, call for a more cautious reassessment of risk and benefit. To our knowledge, this is the first study to systematically quantify the rise in irAEs in ES‐SCLC patients undergoing rechallenge, offering a necessary counterpoint to prior optimistic case‐based evidence [17]. Our study has limitations inherent to its retrospective, single‐center design. Although PSM was used, residual confounding as fundamental limitations may still persist, such as unmeasured clinical factors (e.g., detailed comorbidity indices, nutritional status), disease progression kinetics (e.g., rate of progression, tumor doubling time), variations in supportive care and management of treatment‐related toxicities. Second, the sample size limits the ability of subgroup analysis, which is exploratory and not adjusted for multiple testing, increasing the risk of false‐positive findings. Therefore, these findings need to be validated in independent prospective datasets and multicenter settings. Finally, biomarker data such as PD‐L1 expression, TMB, and molecular subtype classifications were not routinely available for this real‐world cohort. The integration of such biomarkers is crucial to identify the patient subpopulations most likely to benefit from immunotherapy rechallenge. Future studies are warranted to combine biomarkers to guide more personalized treatment strategies in this setting. Conclusion This real‐world study, using PSM to reduce confounding, may not observe a significant improvement in survival outcomes with immunotherapy rechallenge in ES‐SCLC patients following first‐line chemoimmunotherapy, particularly in never‐smokers, and is associated with a higher incidence of irAEs. Future efforts should aim to overcome the challenges posed by SCLC's heterogeneity and immunosuppressive TME, with a focus on applying molecular subtypes and TAM‐related biomarkers to personalize the use of immunotherapies and targeted agents in SCLC to improve efficacy. Therefore, immunotherapy rechallenge for ES‐SCLC should be used with caution in clinical practice, with careful assessment of individual risk–benefit ratios, and its definitive role should be sought through prospective clinical trials. Author Contributions Yuxia Wang: writing – review and editing, writing – original draft, methodology, data curation, validation. Yunfeng Tong: validation, writing – original draft, writing – review and editing, investigation. Yang Pan: formal analysis, writing – original draft, writing – review and editing, data curation. Xinyue Li: writing – review and editing, validation. Hui Li: conceptualization, writing – review and editing, methodology, supervision, funding acquisition. Funding The study was supported by the Natural Science Foundation of Zhejiang Province (grant number LMS26H160013). Ethics Statement The study was approved by the ethics committee of Zhejiang Cancer Hospital (IRB‐2025‐398(IIT)). Consent Informed consent was waived by the Institutional Review Board as this was a retrospective study. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Figure S1: The comparison of two groups of OS using the same or different ICI drugs as the first‐line treatment in the rechallenge group. Figure S2: The OS between the rechallenge and non‐rechallenge groups in SD/PD or CR/PR populations. Figure S3: The OS between the rechallenge and non‐rechallenge groups in PFS ≥ 6 months or PFS < 6 months populations. Figure S4: The OS between the rechallenge and non‐rechallenge groups in oligoprogression or systemic progression populations. Table S1: Standardized mean differences before and after matching. Acknowledgments The authors have nothing to report. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Supplementary Materials Figure S1: The comparison of two groups of OS using the same or different ICI drugs as the first‐line treatment in the rechallenge group. Figure S2: The OS between the rechallenge and non‐rechallenge groups in SD/PD or CR/PR populations. Figure S3: The OS between the rechallenge and non‐rechallenge groups in PFS ≥ 6 months or PFS < 6 months populations. Figure S4: The OS between the rechallenge and non‐rechallenge groups in oligoprogression or systemic progression populations. Table S1: Standardized mean differences before and after matching. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.